2004
DOI: 10.1002/14651858.cd003445.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Supportive care for patients with gastrointestinal cancer

Abstract: 1. To examine e ectiveness/outcomes of best supportive care interventions versus cancer therapies for gastrointestinal cancer trials; 2. To determine whether trials containing best supportive care include a definition of this. Search methodsElectronic databases, grey literature sources, citation searching and reference checking, handsearches of journals and discussion with experts were used to identify potentially eligible trials from both published and unpublished sources up to July 2009. Selection criteriaRC… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
18
0

Year Published

2004
2004
2021
2021

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 32 publications
(21 citation statements)
references
References 22 publications
3
18
0
Order By: Relevance
“…Length of survival of patients who develop widespread or inoperable relapse has steadily improved with current palliative chemotherapy regimes achieving median survival approaching 2 years, compared to 5 mo for best supportive care [34,[42][43][44][45][46][47][48][49][50][51] . There is also evidence that these patients have a stable or improved quality of life, despite side effects during chemotherapy [52,53] . Palliative chemotherapy has been shown to prolong survival and the time to disease progression in asymptomatic patients, as well as duration of the asymptomatic period [54] .…”
Section: Introductionmentioning
confidence: 99%
“…Length of survival of patients who develop widespread or inoperable relapse has steadily improved with current palliative chemotherapy regimes achieving median survival approaching 2 years, compared to 5 mo for best supportive care [34,[42][43][44][45][46][47][48][49][50][51] . There is also evidence that these patients have a stable or improved quality of life, despite side effects during chemotherapy [52,53] . Palliative chemotherapy has been shown to prolong survival and the time to disease progression in asymptomatic patients, as well as duration of the asymptomatic period [54] .…”
Section: Introductionmentioning
confidence: 99%
“…61 It was argued that this type of care should ethically be made available to all treatment groups, meaning that treatment with imatinib or sunitinib could not be provided without concomitant supportive care as well in clinical practice for patients with GIST, although it is possible that treatment with BSC could be provided without additional drug treatment with either imatinib or sunitinib. It should be noted that the amount of care required as part of BSC is likely to increase as the disease progresses and symptoms become worse.…”
Section: Best Supportive Carementioning
confidence: 99%
“…As previously stated, BSC is defined as 'the multi-professional attention to the individual's overall physical, psychosocial, spiritual and cultural needs' . 61 …”
Section: Types Of Intervention and Comparatorsmentioning
confidence: 99%
“…Copyright Best supportive care (BSC) is generally defined as all the interventions and the multiprofessional approach aimed to improve and to optimise QoL in patients affected by progressive diseases, taking into account physical, psychosocial, spiritual and cultural needs. Therapies targeting the disease, such as chemotherapy in cancer, are considered complementary but are not necessarily a part of BSC [10]. As such, it should be clearly distinguished from end-of-life care, adopted to reduce emotional and physical suffering in patients at the very last moments of their life, when active treatments and rehabilitation are no longer meaningful for patients [11,12].…”
Section: Introductionmentioning
confidence: 99%